+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Oncology Drugs Market Research Report by Indication (Bladder Cancer, Breast Cancer, and Cervical Cancer), Drug Class Type, Distribution, State - United States Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 140 Pages
  • July 2022
  • Region: United States
  • 360iResearch™
  • ID: 5123858
UP TO OFF until Dec 31st 2022
The United States Oncology Drugs Market size was estimated at USD 23.20 billion in 2021, USD 26.25 billion in 2022, and is projected to grow at a CAGR 9.62% to reach USD 40.26 billion by 2027.

Market Statistics:


The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Oncology Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Indication, the market was studied across Bladder Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Esophagus Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Prostate Cancer, and Stomach Cancer.
  • Based on Drug Class Type, the market was studied across Chemotherapy, Hormonal Therapy, Immunotherapy, and Targeted Therapy.
  • Based on Distribution, the market was studied across Hospitals Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on State, the market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Oncology Drugs market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Oncology Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Oncology Drugs Market, including AbbVie Inc., Ability Pharma, Acadia Pharmaceuticals Inc., Aegerion Pharmaceuticals Inc., Amgen Inc., ARIAD Pharmaceuticals, Inc., Aslan Pharmaceuticals Ltd.,, Aspen Pharmacare Holdings Limited, Astellas Pharma Inc., AstraZeneca PLC, Athenex, Inc., Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences Inc, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceuticals Industries.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the United States Oncology Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Oncology Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Oncology Drugs Market?
4. What is the competitive strategic window for opportunities in the United States Oncology Drugs Market?
5. What are the technology trends and regulatory frameworks in the United States Oncology Drugs Market?
6. What is the market share of the leading vendors in the United States Oncology Drugs Market?
7. What modes and strategic moves are considered suitable for entering the United States Oncology Drugs Market?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19
6. Oncology Drugs Market, by Indication
6.1. Introduction
6.2. Bladder Cancer
6.3. Breast Cancer
6.4. Cervical Cancer
6.5. Colorectal Cancer
6.6. Esophagus Cancer
6.7. Kidney Cancer
6.8. Liver Cancer
6.9. Lung Cancer
6.10. Prostate Cancer
6.11. Stomach Cancer
7. Oncology Drugs Market, by Drug Class Type
7.1. Introduction
7.2. Chemotherapy
7.3. Hormonal Therapy
7.4. Immunotherapy
7.5. Targeted Therapy
8. Oncology Drugs Market, by Distribution
8.1. Introduction
8.2. Hospitals Pharmacies
8.3. Online Pharmacies
8.4. Retail Pharmacies
9. California Oncology Drugs Market10. Florida Oncology Drugs Market11. Illinois Oncology Drugs Market12. New York Oncology Drugs Market13. Ohio Oncology Drugs Market14. Pennsylvania Oncology Drugs Market15. Texas Oncology Drugs Market
16. Competitive Landscape
16.1. Fpnv Positioning Matrix
16.1.1. Quadrants
16.1.2. Business Strategy
16.1.3. Product Satisfaction
16.2. Market Ranking Analysis
16.3. Market Share Analysis, by Key Player
16.4. Competitive Scenario
16.4.1. Merger & Acquisition
16.4.2. Agreement, Collaboration, & Partnership
16.4.3. New Product Launch & Enhancement
16.4.4. Investment & Funding
16.4.5. Award, Recognition, & Expansion
17. Company Usability Profiles
17.1. Abbvie Inc.
17.2. Ability Pharma
17.3. Acadia Pharmaceuticals Inc.
17.4. Aegerion Pharmaceuticals Inc.
17.5. Amgen Inc.
17.6. Ariad Pharmaceuticals, Inc.
17.7. Aslan Pharmaceuticals Ltd.,
17.8. Aspen Pharmacare Holdings Limited
17.9. Astellas Pharma Inc.
17.10. Astrazeneca plc
17.11. Athenex, Inc.
17.12. Bayer Ag
17.13. Boehringer Ingelheim GmbH
17.14. Bristol-Myers Squibb Company
17.15. Celgene Corporation
17.16. Eli Lilly and Company
17.17. F. Hoffmann-La Roche Ltd.
17.18. Gilead Sciences Inc
17.19. GlaxoSmithKline plc
17.20. Johnson & Johnson Services, Inc.
17.21. Merck & Co., Inc.
17.22. Novartis International Ag
17.23. Pfizer Inc.
17.24. Takeda Pharmaceutical Company Limited
17.25. Teva Pharmaceuticals Industries
18. Appendix
18.1. Discussion Guide
18.2. License & Pricing
List of Figures
FIGURE 1. UNITED STATES ONCOLOGY DRUGS MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, 2021 VS 2027 (USD BILLION)
FIGURE 3. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 4. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 5. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2027
FIGURE 7. UNITED STATES ONCOLOGY DRUGS MARKET DYNAMICS
FIGURE 8. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2021 VS 2027 (%)
FIGURE 9. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2021 VS 2027 (USD BILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2027
FIGURE 11. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY BLADDER CANCER, 2019-2027 (USD BILLION)
FIGURE 12. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY BLADDER CANCER, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 13. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, 2019-2027 (USD BILLION)
FIGURE 14. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 15. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY CERVICAL CANCER, 2019-2027 (USD BILLION)
FIGURE 16. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY CERVICAL CANCER, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 17. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, 2019-2027 (USD BILLION)
FIGURE 18. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 19. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY ESOPHAGUS CANCER, 2019-2027 (USD BILLION)
FIGURE 20. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY ESOPHAGUS CANCER, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 21. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY KIDNEY CANCER, 2019-2027 (USD BILLION)
FIGURE 22. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY KIDNEY CANCER, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 23. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY LIVER CANCER, 2019-2027 (USD BILLION)
FIGURE 24. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY LIVER CANCER, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 25. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2019-2027 (USD BILLION)
FIGURE 26. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 27. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, 2019-2027 (USD BILLION)
FIGURE 28. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 29. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STOMACH CANCER, 2019-2027 (USD BILLION)
FIGURE 30. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STOMACH CANCER, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 31. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS TYPE, 2021 VS 2027 (%)
FIGURE 32. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS TYPE, 2021 VS 2027 (USD BILLION)
FIGURE 33. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS TYPE, 2027
FIGURE 34. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2019-2027 (USD BILLION)
FIGURE 35. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 36. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2019-2027 (USD BILLION)
FIGURE 37. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 38. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2019-2027 (USD BILLION)
FIGURE 39. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 40. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2019-2027 (USD BILLION)
FIGURE 41. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 42. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2021 VS 2027 (%)
FIGURE 43. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2021 VS 2027 (USD BILLION)
FIGURE 44. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2027
FIGURE 45. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, 2019-2027 (USD BILLION)
FIGURE 46. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 47. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2019-2027 (USD BILLION)
FIGURE 48. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 49. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2019-2027 (USD BILLION)
FIGURE 50. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 51. CALIFORNIA ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 52. FLORIDA ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 53. ILLINOIS ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 54. NEW YORK ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 55. OHIO ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 56. PENNSYLVANIA ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 57. TEXAS ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 58. UNITED STATES ONCOLOGY DRUGS MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 59. UNITED STATES ONCOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 60. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES ONCOLOGY DRUGS MARKET, BY TYPE
List of Tables
TABLE 1. UNITED STATES ONCOLOGY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 4. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2019-2027 (USD BILLION)
TABLE 5. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2019-2027 (USD BILLION)
TABLE 6. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY BLADDER CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 7. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 8. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY CERVICAL CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 9. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 10. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY ESOPHAGUS CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 11. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY KIDNEY CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 12. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY LIVER CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 13. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 14. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 15. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STOMACH CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 16. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS TYPE, 2019-2027 (USD BILLION)
TABLE 17. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY STATE, 2019-2027 (USD BILLION)
TABLE 18. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY STATE, 2019-2027 (USD BILLION)
TABLE 19. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY STATE, 2019-2027 (USD BILLION)
TABLE 20. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, BY STATE, 2019-2027 (USD BILLION)
TABLE 21. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD BILLION)
TABLE 22. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY STATE, 2019-2027 (USD BILLION)
TABLE 23. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY STATE, 2019-2027 (USD BILLION)
TABLE 24. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY STATE, 2019-2027 (USD BILLION)
TABLE 25. CALIFORNIA ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 26. CALIFORNIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2019-2027 (USD BILLION)
TABLE 27. CALIFORNIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS TYPE, 2019-2027 (USD BILLION)
TABLE 28. CALIFORNIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD BILLION)
TABLE 29. FLORIDA ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 30. FLORIDA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2019-2027 (USD BILLION)
TABLE 31. FLORIDA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS TYPE, 2019-2027 (USD BILLION)
TABLE 32. FLORIDA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD BILLION)
TABLE 33. ILLINOIS ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 34. ILLINOIS ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2019-2027 (USD BILLION)
TABLE 35. ILLINOIS ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS TYPE, 2019-2027 (USD BILLION)
TABLE 36. ILLINOIS ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD BILLION)
TABLE 37. NEW YORK ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 38. NEW YORK ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2019-2027 (USD BILLION)
TABLE 39. NEW YORK ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS TYPE, 2019-2027 (USD BILLION)
TABLE 40. NEW YORK ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD BILLION)
TABLE 41. OHIO ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 42. OHIO ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2019-2027 (USD BILLION)
TABLE 43. OHIO ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS TYPE, 2019-2027 (USD BILLION)
TABLE 44. OHIO ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD BILLION)
TABLE 45. PENNSYLVANIA ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 46. PENNSYLVANIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2019-2027 (USD BILLION)
TABLE 47. PENNSYLVANIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS TYPE, 2019-2027 (USD BILLION)
TABLE 48. PENNSYLVANIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD BILLION)
TABLE 49. TEXAS ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 50. TEXAS ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2019-2027 (USD BILLION)
TABLE 51. TEXAS ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS TYPE, 2019-2027 (USD BILLION)
TABLE 52. TEXAS ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD BILLION)
TABLE 53. UNITED STATES ONCOLOGY DRUGS MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 54. UNITED STATES ONCOLOGY DRUGS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 55. UNITED STATES ONCOLOGY DRUGS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 56. UNITED STATES ONCOLOGY DRUGS MARKET RANKING
TABLE 57. UNITED STATES ONCOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2021
TABLE 58. UNITED STATES ONCOLOGY DRUGS MARKET MERGER & ACQUISITION
TABLE 59. UNITED STATES ONCOLOGY DRUGS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 60. UNITED STATES ONCOLOGY DRUGS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 61. UNITED STATES ONCOLOGY DRUGS MARKET INVESTMENT & FUNDING
TABLE 62. UNITED STATES ONCOLOGY DRUGS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 63. UNITED STATES ONCOLOGY DRUGS MARKET: LICENSE & PRICING

Companies Mentioned

  • AbbVie Inc.
  • Ability Pharma
  • Acadia Pharmaceuticals Inc.
  • Aegerion Pharmaceuticals Inc.
  • Amgen Inc.
  • ARIAD Pharmaceuticals, Inc.
  • Aslan Pharmaceuticals Ltd.,
  • Aspen Pharmacare Holdings Limited
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Athenex, Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceuticals Industries

Methodology

Loading
LOADING...